BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/16/2020 7:58:40 AM | Browse: 835 | Download: 1634
 |
Received |
|
2019-10-07 09:48 |
|
Peer-Review Started |
|
2019-10-07 09:49 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2019-11-10 05:24 |
|
Revised |
|
2019-11-29 11:02 |
|
Second Decision |
|
2019-12-19 02:57 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-12-22 01:58 |
|
Articles in Press |
|
2019-12-22 01:58 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-01-03 18:04 |
|
Typeset the Manuscript |
|
2020-01-13 11:39 |
|
Publish the Manuscript Online |
|
2020-01-16 07:58 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Idarubicin vs Doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Gael Stéphane Roth, Yann Teyssier, Melodie Abousalihac, Arnaud Seigneurin, Julien Ghelfi, Christian Sengel and Thomas Decaens |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Thomas Decaens, MD, PhD, Full Professor, Department of Hepatology and Gastroenterology, Grenoble-Alpes Universitary Hospital, BP 217, Cedex 09, Grenoble 38043, France. tdecaens@chu-grenoble.fr |
| Key Words |
Hepatocellular carcinoma; Transarterial chemoembolization; Idarubicin; Doxorubicin; Intermediate stage; |
| Core Tip |
Transarterial chemoembolization in the treatment of choice of intermediate stage hepatocellular carcinoma. Doxorubicin is the most used drug without any satisfying evidence of its superiority compared with other drugs. An increasing number of preclinical and early phase clinical studies suggest the superiority of idarubicin anti tumor efficacy in transarterial chemoembolization. With the limits relative to retrospective analysis, this study shows that idarubicin represents an alternative to doxorubicin in the treatment of hepatocellular carcinoma with comparable efficacy and safety. It needs to be confirm by randomized clinical trials. |
| Publish Date |
2020-01-16 07:58 |
| Citation |
Roth GS, Teyssier Y, Abousalihac M, Seigneurin A, Ghelfi J, Sengel C, Decaens T. Idarubicin vs Doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma. World J Gastroenterol 2020; 26(3): 324-334 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i3/324.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i3.324 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
